Ophthalmology remains an attractive segment for private equity investment because of a high rate of procedural growth (3.4% CAGR), the presence of out-of-pocket procedures (LASIK, oculoplastic) and the use of ancillary services (ambulatory surgery centers).
Total investment peaked in 2021, though the average deal size ($15.0M) was lower than that of 2014 ($72.6M). Deal flow slowed in 2022, with 35 deals and an average deal size of $1.2M.
FTI Consulting highlights an aging population leading to strong procedural growth, reimbursement, clinical innovation and emerging medical technologies, practice profitability and the role of Ambulatory Surgical Centers. Read more.
